Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

Summary - Upgrading ARQT to buy due to explosive revenue growth, improving margins, and strong ZORYVE market adoption across multiple indications. - ZORYVE now commands ~41% of non-steroidal topical psoriasis prescriptions, benefiting from dermatologist preference for steroid-sparing options and…